Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Funding Options for R&D in the Life Sciences Sector

Typically, funding for R&D and business growth has been hard to secure over previous years due to the financial crisis. However, now that the financial uncertainty is passing, there is a definite sense of increased confidence in the economy with funding options returning and becoming more readily available and accessible to life sciences businesses. Nigel Greenaway and Laura Herdman of Greenaway Scott discuss the various funding options available and the positive impacts and initiatives these bring to businesses in the life sciences industry.
https://international-pharma.com/wp-content/uploads/2014/10/Foundind-options.pdf

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025